Using Polmacoxib to Reduce Opioid Use After Rotator Cuff Surgery
Perioperative Polmacoxib Reduce Opioid Consumption for Post Operative Pain After Rotator Cuff Tear.
This study tests if Polmacoxib can help people who have rotator cuff surgery use fewer opioids for pain relief after their operation.
Quick facts
| Phase | Not applicable |
|---|---|
| Study type | Interventional |
| Enrollment | 150 (estimated) |
| Ages | 18 Years and up |
| Sex | All |
| Sponsor | Eulji University Hospital Academic / other |
| Locations | 1 site (Uijeongbu-si, Gyeonggi-do) |
| Trial ID | NCT06590714 on ClinicalTrials.gov |
What this trial studies
This clinical trial investigates the effects of Polmacoxib on opioid consumption in patients undergoing surgery for rotator cuff tears. Participants will be randomly assigned to receive either Polmacoxib or standard non-opioid/opioid analgesics post-surgery. The study aims to evaluate whether Polmacoxib can effectively reduce the need for opioids in the postoperative setting. The trial includes thorough informed consent and screening processes to ensure participant eligibility.
Who should consider this trial
Good fit: Ideal candidates are adults over 18 years old requiring surgery for rotator cuff tears with specific MRI findings.
Not a fit: Patients with prior shoulder surgeries, infections, or certain medical conditions may not benefit from this study.
Why it matters
Potential benefit: If successful, this approach could significantly reduce opioid consumption and associated side effects in patients recovering from rotator cuff surgery.
How similar studies have performed: While similar studies have explored opioid-sparing strategies, the specific use of Polmacoxib in this context is novel.
Eligibility criteria
Show full inclusion / exclusion criteria
Inclusion Criteria: * patients over 18 years of age * Patients who need rotator cuff rupture or rotator cuff surgery with MRI identified osteoarthritis (especially small and medium SST dominant rupture) * NSAIDs unadministered patients for more than 1 month * Ultracet unadministered patients for more than 1 month Exclusion Criteria: * primary fiftieth shoulder * including short-lived frozen shoulders * infectious arthritis * previous corticosteroid injections/surgery * moderate-severe arthroplasty * a traumatized patient * a central or peripheral nervous system disease * a mental illness that may not conform to medical or physical therapy * a woman of childbearing age * Pregnancy * a severe gastrointestinal ulcer
Where this trial is running
Uijeongbu-si, Gyeonggi-do
- Uijeongbu Eulji Medical Center, Eulji University — Uijeongbu-si, Gyeonggi-do, South Korea (Recruiting)
Study contacts
- Study coordinator: Jaeman Kwak
- Email: jman.kwak@gmail.com
- Phone: +82 10-2300-6237
How to participate
- Review the eligibility criteria above with your treating physician.
- Visit the official trial page on ClinicalTrials.gov for the most current contact information and recruitment status.
- Contact the listed study coordinator or principal investigator to request pre-screening. Pre-screening is free and never obligates you to enroll.